查看購物車
  • Simplified Chinese
  • English
  • Japanese
心血管設備市場（按產品、適應症、最終用戶和地區分類）- 預測至 2029 年
市場調查報告書
商品編碼
1640831

心血管設備市場（按產品、適應症、最終用戶和地區分類）- 預測至 2029 年

Cardiovascular Devices Market by Product (Cardiac Imaging, Rhythm Management, Cardiac Assist Devices, Interventional Cardiology, Electrophysiology, Monitoring ), Indication (CAD, MI, CHF), End User (Hospitals & Clinics) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 429 Pages | 訂單完成後即時交付

價格

預計2024年全球心血管設備市場規模將達777.1億美元。

預計到 2029 年市場規模將達到 1,103.9 億美元，預測期內複合年成長率為 7.3%。

研究範圍
調查年份 2022-2029
基準年 2023
預測期 2024-2029
考慮單位 金額（美元）
部分 按產品、按適應症、按最終用戶、按地區
目標區域 亞太地區、北美、歐洲、拉丁美洲、中東和非洲

心血管設備市場的成長受到幾個關鍵因素的推動。除此之外，這些還包括全球心血管疾病（CVD）發病率的上升、微創手術的進步、對改善患者治療效果的需求不斷成長，以及對遠端監控的偏好轉變。隨著心臟病發病率的上升，對有效監測和治療的需求也在增加，例如血管成形術、置入術和瓣膜置換術術。藥物釋放型支架、生物可吸收支架和封堵劑的開發以及先進的成像技術等技術創新使得手術更加安全、更精確，促進了市場的成長。

心臟影像影像設備包括一系列用於觀察心臟和評估其功能的醫療技術，可以檢測、診斷和監測心臟疾病。這些機器提供心臟結構、血流和電活動的詳細影像。心臟影像影像領域是心血管設備市場中成長最快的領域。這是由於全球心血管疾病負擔不斷增加、影像技術的進步、早期診斷和精準醫療的重要性日益增加。由於心血管疾病仍然是全球主要的死亡原因，因此需要越來越準確和非侵入性的診斷工具。即時3D超音波心動圖、心臟MRI和AI輔助影像解決方案等醫療保健也將顯著提高患者護理品質的診斷效率，從而促使醫療保健專業人員採用此類設備。除此之外，慢性病的流行增加了心臟相關問題的風險，進一步推動了持續心臟監測和早期檢測的需求。政府舉措和醫療保健報銷政策正在推動已開發市場和新興市場採用先進的診斷影像設備。此外，遠端醫療功能和攜帶式診斷設備使其更容易獲得，支援更廣泛的市場滲透。

當供應心肌的冠狀動脈內積聚斑塊（動脈粥狀硬化）時，就會發生冠狀動脈疾病，導致動脈變窄或阻塞。結果，心肌可能無法獲得足夠的氧氣，導致呼吸短促和心絞痛。冠狀動脈疾病的主要原因包括不健康的生活習慣，如高飽和脂肪飲食、缺乏運動和吸煙，這些習慣會隨著時間的推移而損害動脈。此外，高血壓、高膽固醇、糖尿病和肥胖也會促進斑塊的形成。遺傳、老齡化和慢性壓力也會對心臟和血管產生普遍影響，導致 CAD 的發展。上述因素的發生率上升，加上人們對這些疾病的認知不斷提高，預計將推動市場的成長。

本報告研究了全球心血管設備市場，提供了按產品、適應症、最終用戶、地理趨勢和公司概況分類的市場詳細資訊。

目錄

  • 研究目標
  • 市場定義
  • 市場覆蓋
  • 相關人員

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章 市場概況

  • 介紹
  • 市場動態
  • 產業趨勢
  • 技術分析
  • 波特五力分析
  • 監管狀態
  • 專利分析
  • 貿易分析
  • 定價分析
  • 2024-2025 年的重要會議與活動
  • 主要相關人員和採購標準
  • 心血管設備市場中未滿足的需求/最終用戶期望
  • 人工智慧/生成式人工智慧將如何影響心血管設備市場
  • 生態系分析
  • 案例研究分析
  • 供應鏈分析
  • 鄰近市場分析
  • 影響客戶業務的趨勢/干擾
  • 心血管設備市場：投資與資金籌措狀況
  • 研發產品線分析

6. 心血管設備市場（依產品分類）

  • 介紹
  • 心臟影像影像設備
  • 心率管理設備
  • 介入性心臟病學設備
  • 心臟輔助裝置
  • 電生理學設備
  • 外部支援設備
  • 監控設備

7. 心血管設備市場（依適應症分類）

  • 介紹
  • 冠狀動脈疾病
  • 心律不整
  • 結構性心臟疾病
  • 發炎性心臟疾病
  • 其他

8. 心血管設備市場（依最終用戶分類）

  • 介紹
  • 醫院和診所
  • 診斷實驗室
  • 門診手術中心
  • 其他

9. 心血管設備市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 先進心血管設備產品核可不斷增加推動市場
    • 歐洲宏觀經濟展望
  • 亞太地區
    • 由於患者數量龐大且心血管疾病發生率不斷上升，市場規模不斷擴大
    • 亞太宏觀經濟展望
  • 拉丁美洲
    • 先天性心臟疾病負擔推動市場
    • 拉丁美洲宏觀經濟展望
  • 中東和非洲
    • 醫療保健的成長將支持市場成長
    • 中東和非洲宏觀經濟展望

第10章 競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 收益分析
  • 市場佔有率分析
  • 公司估值矩陣：主要參與企業，2023 年
  • 公司估值矩陣：Start-Ups/中小企業，2023 年
  • 估值及財務指標
  • 品牌/產品比較
  • 競爭場景

第11章 公司簡介

  • 主要參與企業
    • MEDTRONIC
    • ABBOTT LABORATORIES
    • BOSTON SCIENTIFIC CORPORATION
    • GE HEALTHCARE
    • TERUMO CORPORATION
    • EDWARDS LIFESCIENCES CORPORATION
    • SIEMENS HEALTHINEERS AG
    • JOHNSON AND JOHNSON SERVICES, INC.
    • SAHAJANAND MEDICAL TECHNOLOGIES LIMITED
    • BAXTER INTERNATIONAL INC
    • ARTIVION, INC.
    • GETINGE AB
    • KONINKLIJKE PHILIPS NV
    • NIHON KOHDEN CORPORATION
    • BIOTRONIK SE & CO.KG.
    • LEPU MEDICAL TECHNOLOGY（BEIJING）CO., LTD.
    • MICROPORT SCIENTIFIC CORPORATION
    • ANGIODYNAMICS INC.
    • JAPAN LIFELINE CO., LTD.
    • WL GORE & ASSOCIATES
    • B. BRAUN SE
  • 其他公司
    • CANON MEDICAL SYSTEMS CORPORATION
    • PICARD MEDICAL COMPANY
    • BPL MEDICAL TECHNOLOGIES PVT LTD
    • LIFETECH SCIENTIFIC CORPORATION
    • ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED

第12章 附錄

Product Code: MD 9240

The global cardiovascular devices market is USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029, at a CAGR of 7.3 % during the forecast period.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsCardiovascular devices - Product, Indication End user and Region
Regions coveredAsia Pacific, North America, Europe, Latin America, and the Middle East and Africa.

The growth of the cardiovascular devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes and lastly shifting preference to remote monitoring. As rates of heart disease rise, the need for effective monitoring and treatments such as angioplasty, stenting, and valve replacements also increases where these devices are implemented. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds and occluders, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market's growth.

"Based on the product type, the the cardiac imaging and diagnostic device segment holds a significant share the cardiovascular devices market."

Cardiac imaging and diagnostic devices include a range of medical technologies used to visualize the heart and assess its functions, enabling the detection, diagnosis, and monitoring of heart diseases. These devices provide detailed images of the heart's structure, blood flow, and electrical activity. The cardiac imaging and diagnostic devices segment is the one to grow at the highest rate in the cardiovascular devices market. This is due to growing global burden of cardiovascular diseases, advancing imaging technologies, rising importance of early diagnosis, and precision medicine. As it is CVDs remain the leading cause of mortality throughout the world, demands increasingly accurate and non-invasive diagnostic tools. Advancements like real-time 3D echocardiography, cardiac MRI, and AI-assisted imaging solutions also significantly enhance the diagnostic efficiency concerning the quality of care for patients and lead to the adoption of such devices among healthcare providers. Apart from this, prevalence of chronic diseases, which increases the risk for heart-related issues, further presses upon continuous cardiac monitoring and the demand for early detection. Government initiatives and healthcare reimbursement policies in the advanced as well as emerging markets drive the adoption of advanced imaging devices. Telehealth capabilities and portable diagnostic devices also make it more accessible, supporting broader market penetration.

"The Coronary artery disease segment holds the largest market share in cardiovascular devices market."

Coronary heart disease occurs when plaque (atherosclerosis) builds up inside the coronary arteries, that feed blood to the heart muscle, and narrows or blocks them. Thereby, breathlessness or angina may result from heart muscle not receiving enough oxygen rich blood. In extreme cases, heart attack or myocardial infarction may occur due to a total blockage of the coronary artery.Some of the major causes for CAD include an unhealthy lifestyle, including a diet full of saturated fats, lack of exercise, and smoking, which cause damage to the arteries over time. Other factors that contribute to this condition include hypertension, high cholesterol levels, diabetes, and obesity, all of which further the development of plaque. Genetic disposition, age, and chronic stress also add to the development of CAD due to their general impact on the heart and blood vessels. The increasing incidence of the above factors coupled with hightened awareness among the popuation regarding therse diseases would aid in market growth.

"Based on the end user, Others segment is expected to grow by the significant CAGR in the cardiovascular devices market.

The "others" segment, which includes applications like general health checkup, fitness, and wellness monitoring, intraoperative monitoring, and post-op care, is growing the fastest in the cardiovascular device market. This is because of increased focus on preventive care, personalized medicine, and holistic patient care. With the ever-growing awareness on the importance of regular cardiovascular monitoring, there are growing demands for wearable and connected devices which measure parameters including heart rate, blood pressure, and ECG among healthy patients and chronic diseases patients. Advanced intraoperative monitoring equipment during surgery helps assess patients' hearts real time in safety for patient comfort and best surgical results. Additionally, monitoring devices post-surgery will help track the recovery, early detection of complications, and minimize hospital readmission rates. Integration of AI and IoT into these devices improves the accuracy of data, patient engagement, and clinician decision-making. On the other hand, adoption of telehealth and remote patient monitoring technologies is growing and allows the continuation of care outside the clinical setting.

"Asia Pacific to grow with the highest CAGR in the Cardiovascular devices market during the forecast period."

The Asia-Pacific region is also expected to experience maximum growth in the cardiovascular devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.

The break up of the profile of primary participants in the cardiovascular devices market:

  • By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
  • By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
  • By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

Key players in the cardiovascular devices market

Some of the prominent players operating in the cardiovascular devices market include Medtronic Plc (Ireland), Abbott Laboratories (US), Boston Scientific Corporation (US), Terumo Corporation (Japan), GE Healthcare Technologies, Inc. (US), Edward Lifesciences Corporation (US), Siemens Healthineers AG (Germany), Johnson & Johnson (US), Baxter International Inc (US), B. Braun SE (Germany), Getinge AB (Sweden), Koninklijke Philips N.V. (Netherlands), Lepu Medical Technology (Beijing) Co., Ltd (China), Nihon Kohden Corporation (Japan), MicroPort Scientific Corporation (China), Japan Lifeline Co., Ltd. (Japan), AngioDynamics, Inc.(US), LifeTech Scientific Corporation (China), Artivion Inc (US), Sahajanand Medical Technologies Limited (India), OrbusNeich Medical Group Holdings Limited (China), BPL Medical Technologies (India), BiotroniK. (Germany),), W.L. Gore & Associates, Inc (US), Canon medical systems corporation (Japan), Picard Medical Company (US).

Research Coverage:

The report analyzes the cardiovascular devices market and aims at estimating the market size and future growth potential of this market based on various segments such as products, indication and end user. The report also includes a product portfolio matrix of various cardiovascular device technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cardiovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

  • Of Analysis of key drivers (The increase in prevalence of cardiovascular diseases, The increasing preference for minimally invasive techniques, Technological Advancements Fueling Innovation in Cardiovascular Devices, Rise in Remote Patient Monitoring), restraints (Stringent regulatory guidelines for product approval, Lack of skilled Cardiovascular Healthcare professionals), opportunities (Projected Growth in the Elderly Population, Emerging Opportunities in Biodegradable Cardiovascular Devices) and challenges (Product failures and recalls, Adverse Effects and Complications with usage of implantable cardiovascular devices).
  • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global cardiovascular devicesmarket.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global cardiovascular devices market
  • Market Development: Comprehensive information on the lucrative emerging markets by product, indication and enduser.
  • Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global cardiovascular devices market.
  • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global cardiovascular devices market.

TABLE OF CONTENTS

A1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 GROWTH FORECAST
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 MARKET RANKING ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CARDIOVASCULAR DEVICES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER AND COUNTRY (2023)
  • 4.3 CARDIOVASCULAR DEVICES MARKET: REGIONAL MIX, 2024-2029 (USD MILLION)

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of cardiovascular diseases
      • 5.2.1.2 Increasing accessibility to advanced high-performance devices
      • 5.2.1.3 Growing preference for minimally invasive surgeries
      • 5.2.1.4 Rising technological advancements in cardiovascular devices
      • 5.2.1.5 Increasing trend of remote patient monitoring
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent regulatory guidelines for product approval
      • 5.2.2.2 Shortage of skilled cardiac health professionals
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising geriatric population and increasing uptake of CVD devices
      • 5.2.3.2 Emergence of biodegradable cardiovascular devices
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Product recalls & failures
      • 5.2.4.2 Complications associated with implantable devices
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 MINIMALLY INVASIVE PROCEDURES
    • 5.3.2 WEARABLE TECHNOLOGY AND REMOTE MONITORING
    • 5.3.3 PERSONALIZED MEDICINE
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Transcatheter aortic valve replacement (TAVR)
      • 5.4.1.2 Cardiac mapping systems
      • 5.4.1.3 3D-printed cardiovascular devices
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Robotic-assisted surgeries
      • 5.4.2.2 Advanced catheter systems
      • 5.4.2.3 Imaging technologies
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Regenerative medicine
      • 5.4.3.2 Biomaterials & nanotechnology
      • 5.4.3.3 Big data & cloud computing
  • 5.5 PORTER'S FIVE FORCE ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 BARGAINING POWER OF SUPPLIERS
    • 5.5.3 BARGAINING POWER OF BUYERS
    • 5.5.4 THREAT OF SUBSTITUTES
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 REGULATORY ANALYSIS
      • 5.6.1.1 North America
        • 5.6.1.1.1 US
        • 5.6.1.1.2 Canada
      • 5.6.1.2 Europe
      • 5.6.1.3 Asia Pacific
      • 5.6.1.4 Latin America
      • 5.6.1.5 Middle East & Africa
    • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 PATENT ANALYSIS
    • 5.7.1 PATENT PUBLICATION TRENDS IN CARDIOVASCULAR DEVICES MARKET
    • 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.8 TRADE ANALYSIS
  • 5.9 PRICING ANALYSIS
  • 5.10 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.11.2 BUYING CRITERIA
  • 5.12 UNMET NEEDS/END-USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET
  • 5.13 IMPACT OF AI/GENERATIVE AI ON CARDIOVASCULAR DEVICES MARKET
  • 5.14 ECOSYSTEM ANALYSIS
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 CASE STUDY 1: EVALUATION OF TAVR SYSTEM
    • 5.15.2 CASE STUDY 2: SAFETY & EFFICACY ASSESSMENT OF WATCHMAN DEVICE IN ATRIAL FIBRILLATION
    • 5.15.3 CASE STUDY 3: PERFORMANCE ANALYSIS OF MITRACLIP FOR THE TREATMENT OF MITRAL REGURGITATION
  • 5.16 SUPPLY CHAIN ANALYSIS
  • 5.17 ADJACENT MARKET ANALYSIS
    • 5.17.1 CARDIAC MONITORING AND RHYTHM MANAGEMENT DEVICES MARKET
  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.19 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO
  • 5.20 R&D PIPELINE ANALYSIS

6 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 CARDIAC IMAGING & DIAGNOSTIC DEVICES
    • 6.2.1 ECG DEVICES
      • 6.2.1.1 Low costs and expanding applications to fuel market
    • 6.2.2 CARDIAC ULTRASOUND IMAGING
      • 6.2.2.1 Growing preference towards minimally invasive techniques to boost demand
    • 6.2.3 CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCANNERS
      • 6.2.3.1 Increasing preference over other diagnostic imaging methods to drive market
    • 6.2.4 CARDIAC MAGNETIC RESONANCE IMAGING (MRI)
      • 6.2.4.1 Increasing incidence of cardiac diseases to fuel uptake
    • 6.2.5 NUCLEAR CARDIOLOGY SYSTEMS
      • 6.2.5.1 Ability to assess tissue functionality and heart physiology to support market growth
    • 6.2.6 CARDIAC DIAGNOSTIC CATHETERS
      • 6.2.6.1 Rising focus on catheterization procedures to fuel market
  • 6.3 CARDIAC RHYTHM MANAGEMENT DEVICES
    • 6.3.1 PACEMAKERS
      • 6.3.1.1 Growing availability of leadless and MRI-safe devices to boost demand
    • 6.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
      • 6.3.2.1 Increasing prevalence of arrhythmias to drive market
    • 6.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES
      • 6.3.3.1 Ability to reduce fatigue and associated heart failure symptoms to boost demand
  • 6.4 INTERVENTIONAL CARDIOLOGY DEVICES
    • 6.4.1 CORONARY STENTS
      • 6.4.1.1 Technological advancements in stents to fuel uptake
    • 6.4.2 HEART VALVE DEVICES
      • 6.4.2.1 Increasing prevalence of valve stenosis and regurgitation to fuel market
    • 6.4.3 CLOSURE DEVICES
      • 6.4.3.1 Utilization of self-expandable materials to drive market
    • 6.4.4 SURGICAL CATHETERS
      • 6.4.4.1 Rising adoption of angioplasty procedures to support market growth
    • 6.4.5 GUIDEWIRES
      • 6.4.5.1 Rising uptake in PCI procedures to drive market
    • 6.4.6 OTHER INTERVENTIONAL CARDIOLOGY DEVICES
  • 6.5 CARDIAC ASSIST DEVICES
    • 6.5.1 VENTRICULAR ASSIST DEVICES
      • 6.5.1.1 Rising incidence of heart failure to boost market
    • 6.5.2 INTRA-AORTIC BALLOON PUMPS (IABP)
      • 6.5.2.1 Product recalls to restrain market
    • 6.5.3 TOTAL ARTIFICIAL HEART (TAH)
      • 6.5.3.1 Growing product pipeline to fuel market
    • 6.5.4 IMPELLA DEVICES
      • 6.5.4.1 Increasing utility in high-risk procedures to support market growth
  • 6.6 ELECTROPHYSIOLOGY DEVICES
    • 6.6.1 EP CATHETERS
      • 6.6.1.1 Rising incidence of chronic heart conditions to drive market
    • 6.6.2 ABLATION SYSTEMS
      • 6.6.2.1 Increasing utilization of radiofrequency ablation procedures to support market growth
    • 6.6.3 3D MAPPING SYSTEM
      • 6.6.3.1 Development of alternative technologies to hinder market
  • 6.7 EXTERNAL SUPPORT DEVICES
    • 6.7.1 EXTERNAL DEFIBRILLATORS
      • 6.7.1.1 Adoption of user-friendly AEDs to fuel market
    • 6.7.2 EXTERNAL PACEMAKERS
      • 6.7.2.1 Technological advancements in leadless & implantable pacemakers to restrain market
    • 6.7.3 CARDIAC COMPRESSION DEVICES
      • 6.7.3.1 Reduced CPR rate to restrain market
  • 6.8 MONITORING DEVICES
    • 6.8.1 BLOOD PRESSURE MONITORS
      • 6.8.1.1 Portability and ease of use to fuel market
    • 6.8.2 PULSE OXIMETERS
      • 6.8.2.1 Increasing adoption of OTC devices in home care settings to propel market
    • 6.8.3 IMPLANTABLE CARDIAC MONITORS (ICM)
      • 6.8.3.1 Growing focus on RPM to support market

7 CARDIOVASCULAR DEVICES MARKET, BY INDICATION

  • 7.1 INTRODUCTION
  • 7.2 CORONARY ARTERY DISEASE
    • 7.2.1 ANGINA PECTORIS
      • 7.2.1.1 Growing adoption of implantable monitors and ECG devices for treatment to drive market
    • 7.2.2 MYOCARDIAL INFARCTION
      • 7.2.2.1 Increasing demand for stents in acute cases to fuel market
  • 7.3 ARRHYTHMIAS
    • 7.3.1 TACHYCARDIA
      • 7.3.1.1 Rising cardiac electrophysiology procedures to drive market
    • 7.3.2 BRADYCARDIA
      • 7.3.2.1 Rising incidence of OSA to support market growth
  • 7.4 STRUCTURAL HEART DISEASE
    • 7.4.1 VALVULAR HEART DISEASE
      • 7.4.1.1 Rising risks of aortic stenosis to drive market
    • 7.4.2 CONGENITAL HEART DISEASE
      • 7.4.2.1 Potential for new therapies to fuel uptake
    • 7.4.3 CARDIOMYOPATHY
      • 7.4.3.1 Uptake of ICDs to drive market
    • 7.4.4 CONGESTIVE HEART FAILURE
      • 7.4.4.1 Growth in geriatric population to fuel market
  • 7.5 INFLAMMATORY HEART DISEASE
    • 7.5.1 PERICARDITIS
      • 7.5.1.1 Increasing incidence due to COVID-19 to support market growth
    • 7.5.2 MYOCARDITIS
      • 7.5.2.1 Increasing prevalence of autoimmune diseases to support market growth
    • 7.5.3 ENDOCARDITIS
      • 7.5.3.1 Focus on echocardiography for clinical evaluation to drive market
  • 7.6 OTHER CARDIOVASCULAR INDICATIONS

8 CARDIOVASCULAR DEVICES MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS & CLINCS
    • 8.2.1 HIGH PURCHASING POWER OF HOSPITALS AND RISING NUMBER OF CARDIOVASCULAR PROCEDURES TO DRIVE MARKET
  • 8.3 DIAGNOSTIC LABORATORIES
    • 8.3.1 RISING FOCUS ON TECHNOLOGICALLY ADVANCED DIAGNOSTIC INSTRUMENTS TO SUPPORT MARKET GROWTH
  • 8.4 AMBULATORY SURGERY CENTERS
    • 8.4.1 INCREASING DEMAND FOR OUTPATIENT CARE AND RPM SERVICES TO PROPEL MARKET
  • 8.5 OTHER END USERS

9 CARDIOVASCULAR DEVICES MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 9.2.2 US
      • 9.2.2.1 Increasing cases of obesity due to sedentary lifestyles to propel market
    • 9.2.3 CANADA
      • 9.2.3.1 Increasing funding for CVD research to support market growth
  • 9.3 EUROPE
    • 9.3.1 INCREASING PRODUCT APPROVALS FOR ADVANCED CARDIOVASCULAR DEVICES TO DRIVE MARKET
    • 9.3.2 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 LARGE TARGET PATIENT POPULATION AND INCREASING INCIDENCE OF CVD TO PROPEL MARKET
    • 9.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 BURDEN OF CONGENITAL HEART DISEASES TO DRIVE MARKET
    • 9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 RISING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH
    • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIOVASCULAR DEVICES MARKET
  • 10.3 REVENUE ANALYSIS
  • 10.4 MARKET SHARE ANALYSIS
    • 10.4.1 RANKING OF KEY MARKET PLAYERS, 2023
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 10.5.5.1 Company footprint
      • 10.5.5.2 Region footprint
      • 10.5.5.3 Product footprint
      • 10.5.5.4 Indication footprint
      • 10.5.5.5 End-user footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 10.7 COMPANY VALUATION & FINANCIAL METRICS
    • 10.7.1 COMPANY VALUATION
    • 10.7.2 FINANCIAL METRICS
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    • 10.9.1 PRODUCT LAUNCHES & APPROVALS
    • 10.9.2 DEALS
    • 10.9.3 EXPANSIONS
    • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
    • 11.1.1 MEDTRONIC
      • 11.1.1.1 Business overview
      • 11.1.1.2 Products offered
      • 11.1.1.3 Recent developments
        • 11.1.1.3.1 Product launches & approvals
        • 11.1.1.3.2 Deals
      • 11.1.1.4 MnM view
        • 11.1.1.4.1 Key strengths
        • 11.1.1.4.2 Strategic choices
        • 11.1.1.4.3 Weaknesses & competitive threats
    • 11.1.2 ABBOTT LABORATORIES
      • 11.1.2.1 Business overview
      • 11.1.2.2 Products offered
      • 11.1.2.3 Recent developments
        • 11.1.2.3.1 Product launches & approvals
        • 11.1.2.3.2 Deals
      • 11.1.2.4 MnM view
        • 11.1.2.4.1 Key strengths
        • 11.1.2.4.2 Strategic choices
        • 11.1.2.4.3 Weaknesses & competitive threats
    • 11.1.3 BOSTON SCIENTIFIC CORPORATION
      • 11.1.3.1 Business overview
      • 11.1.3.2 Products offered
      • 11.1.3.3 Recent developments
        • 11.1.3.3.1 Product launches & approvals
        • 11.1.3.3.2 Deals
      • 11.1.3.4 MnM view
        • 11.1.3.4.1 Key strengths
        • 11.1.3.4.2 Strategic choices
        • 11.1.3.4.3 Weaknesses & competitive threats
    • 11.1.4 GE HEALTHCARE
      • 11.1.4.1 Business overview
      • 11.1.4.2 Products offered
      • 11.1.4.3 Recent developments
        • 11.1.4.3.1 Product launches & approvals
        • 11.1.4.3.2 Deals
      • 11.1.4.4 MnM view
        • 11.1.4.4.1 Key strengths
        • 11.1.4.4.2 Strategic choices
        • 11.1.4.4.3 Weaknesses & competitive threats
    • 11.1.5 TERUMO CORPORATION
      • 11.1.5.1 Business overview
      • 11.1.5.2 Products offered
      • 11.1.5.3 Recent developments
        • 11.1.5.3.1 Product launches & approvals
      • 11.1.5.4 MnM view
        • 11.1.5.4.1 Key strengths
        • 11.1.5.4.2 Strategic choices
        • 11.1.5.4.3 Weaknesses & competitive threats
    • 11.1.6 EDWARDS LIFESCIENCES CORPORATION
      • 11.1.6.1 Business overview
      • 11.1.6.2 Products offered
      • 11.1.6.3 Recent developments
        • 11.1.6.3.1 Product launches & approvals
        • 11.1.6.3.2 Deals
    • 11.1.7 SIEMENS HEALTHINEERS AG
      • 11.1.7.1 Business overview
      • 11.1.7.2 Products offered
      • 11.1.7.3 Recent developments
        • 11.1.7.3.1 Product launches & approvals
    • 11.1.8 JOHNSON AND JOHNSON SERVICES, INC.
      • 11.1.8.1 Business overview
      • 11.1.8.2 Products offered
      • 11.1.8.3 Recent developments
        • 11.1.8.3.1 Product launches & approvals
        • 11.1.8.3.2 Deals
    • 11.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED
      • 11.1.9.1 Business overview
      • 11.1.9.2 Products offered
    • 11.1.10 BAXTER INTERNATIONAL INC
      • 11.1.10.1 Business overview
      • 11.1.10.2 Products offered
      • 11.1.10.3 Recent developments
        • 11.1.10.3.1 Deals
    • 11.1.11 ARTIVION, INC.
      • 11.1.11.1 Business overview
      • 11.1.11.2 Products offered
    • 11.1.12 GETINGE AB
      • 11.1.12.1 Business overview
      • 11.1.12.2 Products offered
      • 11.1.12.3 Recent developments
        • 11.1.12.3.1 Product launches & approvals
        • 11.1.12.3.2 Deals
    • 11.1.13 KONINKLIJKE PHILIPS N.V.
      • 11.1.13.1 Business overview
      • 11.1.13.2 Products offered
      • 11.1.13.3 Recent developments
        • 11.1.13.3.1 Product launches & approvals
    • 11.1.14 NIHON KOHDEN CORPORATION
      • 11.1.14.1 Business overview
      • 11.1.14.2 Products offered
    • 11.1.15 BIOTRONIK SE & CO.KG.
      • 11.1.15.1 Business overview
      • 11.1.15.2 Products offered
    • 11.1.16 LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD.
      • 11.1.16.1 Business overview
      • 11.1.16.2 Products offered
      • 11.1.16.3 Recent developments
        • 11.1.16.3.1 Product launches & approvals
    • 11.1.17 MICROPORT SCIENTIFIC CORPORATION
      • 11.1.17.1 Business overview
      • 11.1.17.2 Products offered
      • 11.1.17.3 Recent developments
        • 11.1.17.3.1 Product launches & approvals
    • 11.1.18 ANGIODYNAMICS INC.
      • 11.1.18.1 Business overview
      • 11.1.18.2 Products offered
    • 11.1.19 JAPAN LIFELINE CO., LTD.
      • 11.1.19.1 Business overview
      • 11.1.19.2 Products offered
      • 11.1.19.3 Recent developments
        • 11.1.19.3.1 Product launches & approvals
    • 11.1.20 W.L. GORE & ASSOCIATES
      • 11.1.20.1 Business overview
      • 11.1.20.2 Products offered
    • 11.1.21 B. BRAUN SE
      • 11.1.21.1 Business overview
      • 11.1.21.2 Products offered
  • 11.2 OTHER PLAYERS
    • 11.2.1 CANON MEDICAL SYSTEMS CORPORATION
    • 11.2.2 PICARD MEDICAL COMPANY
    • 11.2.3 BPL MEDICAL TECHNOLOGIES PVT LTD
    • 11.2.4 LIFETECH SCIENTIFIC CORPORATION
    • 11.2.5 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 CURRENCY CONVERSION RATES
  • TABLE 2 CARDIOVASCULAR DEVICES MARKET: STUDY ASSUMPTIONS
  • TABLE 3 CARDIOVASCULAR DEVICES MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 4 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT DEVICES
  • TABLE 5 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 LIST OF PATENTS IN CARDIOVASCULAR DEVICES MARKET, 2014-2024
  • TABLE 12 IMPORT DATA FOR CARDIOVASCULAR DEVICES MARKET, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 13 EXPORT DATA FOR CARDIOVASCULAR DEVICES, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 14 CARDIOVASCULAR DEVICES MARKET: AVERAGE SELLING PRICE, BY PRODUCT (2023)
  • TABLE 15 AVERAGE SELLING PRICE TREND OF CARDIOVASCULAR DEVICES, BY REGION (2023)
  • TABLE 16 CARDIOVASCULAR DEVICES MARKET: KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS
  • TABLE 18 KEY BUYING CRITERIA FOR TOP 3 END USERS OF CARDIOVASCULAR DEVICES
  • TABLE 19 CARDIOVASCULAR DEVICES MARKET: UNMET NEEDS
  • TABLE 20 CARDIOVASCULAR DEVICES MARKET: END-USER EXPECTATIONS
  • TABLE 21 CARDIOVASCULAR DEVICES MARKET: IMPACT OF AI/GENERATIVE AI
  • TABLE 22 CARDIOVASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS
  • TABLE 23 CARDIOVASCULAR DEVICES MARKET: R&D PIPELINE ANALYSIS
  • TABLE 24 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 25 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 26 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 27 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 28 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 29 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 30 ECG DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 31 ECG DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 32 CARDIAC ULTRASOUND IMAGING MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 33 CARDIAC ULTRASOUND IMAGING MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 34 CARDIAC CT SCANNERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 35 CARDIAC CT SCANNERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 36 CARDIAC MRI MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 37 CARDIAC MRI MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 38 NUCLEAR CARDIOLOGY SYSTEMS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 39 NUCLEAR CARDIOLOGY SYSTEMS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 40 CARDIAC DIAGNOSTIC CATHETERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 41 CARDIAC DIAGNOSTIC CATHETERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 42 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 43 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 44 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 45 CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 46 CARDIOVASCULAR DEVICES MARKET: LIST OF COMPANIES WITH KEY PRODUCTS
  • TABLE 47 PACEMAKERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 48 PACEMAKERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 49 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 50 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 51 CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 52 CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 53 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 54 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 55 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 56 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 57 CORONARY STENTS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 58 CORONARY STENTS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 59 HEART VALVE DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 60 HEART VALVE DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 61 CLOSURE DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 62 CLOSURE DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 63 SURGICAL CATHETERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 64 SURGICAL CATHETERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 65 GUIDEWIRES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 66 GUIDEWIRES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 67 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 68 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 69 CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 70 CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 71 CARDIAC ASSIST DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 72 CARDIAC ASSIST DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 73 VENTRICULAR ASSIST DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 74 VENTRICULAR ASSIST DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 75 INTRA-AORTIC BALLOON PUMPS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 76 INTRA-AORTIC BALLOON PUMPS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 77 TOTAL ARTIFICIAL HEART MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 78 TOTAL ARTIFICIAL HEART MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 79 IMPELLA DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 80 IMPELLA DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 81 ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 82 ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 83 ELECTROPHYSIOLOGY DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 84 ELECTROPHYSIOLOGY DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 85 EP CATHETERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 86 EP CATHETERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 87 ABLATION SYSTEMS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 88 ABLATION SYSTEMS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 89 3D MAPPING SYSTEMS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 90 3D MAPPING SYSTEMS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 91 EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 92 EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 93 EXTERNAL SUPPORT DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 94 EXTERNAL SUPPORT DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 95 EXTERNAL DEFIBRILLATORS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 96 EXTERNAL DEFIBRILLATORS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 97 EXTERNAL PACEMAKERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 98 EXTERNAL PACEMAKERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 99 CARDIAC COMPRESSION DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 100 CARDIAC COMPRESSION DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 101 CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 102 CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 103 CARDIOVASCULAR MONITORING DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 104 CARDIOVASCULAR MONITORING DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 105 BLOOD PRESSURE MONITORS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 106 BLOOD PRESSURE MONITORS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 107 PULSE OXIMETERS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 108 PULSE OXIMETERS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 109 IMPLANTABLE CARDIAC MONITORS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 110 IMPLANTABLE CARDIAC MONITORS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 111 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 112 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 113 CORONARY ARTERY DISEASE MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 114 CORONARY ARTERY DISEASE MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 115 CORONARY ARTERY DISEASE MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 116 CORONARY ARTERY DISEASE MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 117 CORONARY ARTERY DISEASE MARKET FOR ANGINA PECTORIS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 118 CORONARY ARTERY DISEASE MARKET FOR ANGINA PECTORIS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 119 CORONARY ARTERY DISEASE MARKET FOR MYOCARDIAL INFRACTION, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 120 CORONARY ARTERY DISEASE MARKET FOR MYOCARDIAL INFRACTION, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 121 ARRHYTHMIAS MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 122 ARRHYTHMIAS MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 123 ARRHYTHMIAS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 124 ARRHYTHMIAS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 125 ARRHYTHMIAS MARKET FOR TACHYCARDIA, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 126 ARRHYTHMIAS MARKET FOR TACHYCARDIA, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 127 ARRHYTHMIAS MARKET FOR BRADYCARDIA, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 128 ARRHYTHMIAS MARKET FOR BRADYCARDIA, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 129 STRUCTURAL HEART DISEASE MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 130 STRUCTURAL HEART DISEASE MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 131 STRUCTURAL HEART DISEASE MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 132 STRUCTURAL HEART DISEASE MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 133 VALVULAR HEART DISEASE MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 134 VALVULAR HEART DISEASE MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 135 CONGENITAL HEART DISEASE MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 136 CONGENITAL HEART DISEASE MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 137 CARDIOMYOPATHY MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 138 CARDIOMYOPATHY MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 139 CONGESTIVE HEART FAILURE MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 140 CONGESTIVE HEART FAILURE MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 141 INFLAMMATORY HEART DISEASE MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 142 INFLAMMATORY HEART DISEASE MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 143 INFLAMMATORY HEART DISEASE MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 144 INFLAMMATORY HEART DISEASE MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 145 INFLAMMATORY HEART DISEASE MARKET FOR PERICARDITIS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 146 INFLAMMATORY HEART DISEASE MARKET FOR PERICARDITIS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 147 INFLAMMATORY HEART DISEASE MARKET FOR MYOCARDITIS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 148 INFLAMMATORY HEART DISEASE MARKET FOR MYOCARDITIS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 149 INFLAMMATORY HEART DISEASE MARKET FOR ENDOCARDITIS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 150 INFLAMMATORY HEART DISEASE MARKET FOR ENDOCARDITIS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 151 OTHER CARDIOVASCULAR INDICATIONS MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 152 OTHER CARDIOVASCULAR INDICATIONS MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 153 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 154 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 155 CARDIOVASCULAR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 156 CARDIOVASCULAR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 157 CARDIOVASCULAR DEVICES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 158 CARDIOVASCULAR DEVICES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 159 CARDIOVASCULAR DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 160 CARDIOVASCULAR DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 161 CARDIOVASCULAR DEVICES MARKET FOR OTHER END USERS, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 162 CARDIOVASCULAR DEVICES MARKET FOR OTHER END USERS, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 163 CARDIOVASCULAR DEVICES MARKET, BY REGION, 2021-2023 (USD MILLION)
  • TABLE 164 CARDIOVASCULAR DEVICES MARKET, BY REGION, 2024-2029 (USD MILLION)
  • TABLE 165 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY COUNTRY, 2021-2023 (USD MILLION)
  • TABLE 166 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY COUNTRY, 2024-2029 (USD MILLION)
  • TABLE 167 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 168 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 169 NORTH AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 170 NORTH AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 171 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 172 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 174 NORTH AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 175 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 176 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 177 NORTH AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 178 NORTH AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 179 NORTH AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 180 NORTH AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 181 NORTH AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 182 NORTH AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 184 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 185 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 186 NORTH AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 187 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 188 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 189 NORTH AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 190 NORTH AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 191 NORTH AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 192 NORTH AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 193 NORTH AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 194 NORTH AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 195 NORTH AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 196 NORTH AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 197 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 198 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 199 US: KEY MACROINDICATORS
  • TABLE 200 US: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 201 US: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 202 US: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 203 US: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 204 US: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 205 US: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 206 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 207 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 208 US: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 209 US: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 210 US: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 211 US: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 212 US: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 213 US: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 214 US: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 215 US: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 216 US: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 217 US: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 218 US: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 219 US: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 220 US: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 221 US: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 222 US: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 223 US: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 224 US: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 225 US: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 226 US: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 227 US: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 228 CANADA: KEY MACROINDICATORS
  • TABLE 229 CANADA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 230 CANADA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 231 CANADA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 232 CANADA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 233 CANADA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 234 CANADA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 235 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 236 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 237 CANADA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 238 CANADA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 239 CANADA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 240 CANADA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 241 CANADA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 242 CANADA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 243 CANADA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 244 CANADA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 245 CANADA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 246 CANADA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 247 CANADA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 248 CANADA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 249 CANADA: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 250 CANADA: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 251 CANADA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 252 CANADA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 253 CANADA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 254 CANADA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 255 CANADA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 256 CANADA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 257 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 258 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 259 EUROPE: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 260 EUROPE: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 261 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 262 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 263 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 264 EUROPE: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 265 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 266 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 267 EUROPE: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 268 EUROPE: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 269 EUROPE: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 270 EUROPE: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 271 EUROPE: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 272 EUROPE: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 273 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 274 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 275 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 276 EUROPE: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 277 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 278 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 279 EUROPE: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 280 EUROPE: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 281 EUROPE: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 282 EUROPE: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 283 EUROPE: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 284 EUROPE: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 285 EUROPE: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 286 EUROPE: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 287 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 288 EUROPE: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 289 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 290 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 291 ASIA PACIFIC: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 292 ASIA PACIFIC: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 293 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 295 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 296 ASIA PACIFIC: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 297 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 298 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 299 ASIA PACIFIC: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 300 ASIA PACIFIC: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 301 ASIA PACIFIC: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 302 ASIA PACIFIC: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 303 ASIA PACIFIC: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 304 ASIA PACIFIC: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 305 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 306 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 307 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 308 ASIA PACIFIC: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 309 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 310 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 311 ASIA PACIFIC: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 312 ASIA PACIFIC: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 314 ASIA PACIFIC: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 318 ASIA PACIFIC: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 320 ASIA PACIFIC: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 321 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 322 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 323 LATIN AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 324 LATIN AMERICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 325 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 326 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 327 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 328 LATIN AMERICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 329 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 330 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 331 LATIN AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 332 LATIN AMERICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 333 LATIN AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 334 LATIN AMERICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 335 LATIN AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 336 LATIN AMERICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 337 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 338 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 339 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 340 LATIN AMERICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 341 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 342 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 343 LATIN AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 344 LATIN AMERICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 345 LATIN AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 346 LATIN AMERICA: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 347 LATIN AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 348 LATIN AMERICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 349 LATIN AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 350 LATIN AMERICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 351 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 352 LATIN AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2021-2023 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024-2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 357 MIDDLE EAST & AFRICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 359 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY CARDIAC RHYTHM MANAGEMENT DEVICES, 2021-2023 (THOUSAND UNITS)
  • TABLE 360 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY CARDIAC RHYTHM MANAGEMENT DEVICES, 2024-2029 (THOUSAND UNITS)
  • TABLE 361 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 362 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 364 MIDDLE EAST & AFRICA: CARDIAC ASSIST DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 365 MIDDLE EAST & AFRICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 366 MIDDLE EAST & AFRICA: ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 367 MIDDLE EAST & AFRICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 368 MIDDLE EAST & AFRICA: EXTERNAL SUPPORT DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 369 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (USD MILLION)
  • TABLE 370 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (USD MILLION)
  • TABLE 371 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2021-2023 (THOUSAND UNITS)
  • TABLE 372 MIDDLE EAST & AFRICA: CARDIOVASCULAR MONITORING DEVICES MARKET, BY TYPE, 2024-2029 (THOUSAND UNITS)
  • TABLE 373 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 374 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 375 MIDDLE EAST & AFRICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 376 MIDDLE EAST & AFRICA: CORONARY ARTERY DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 377 MIDDLE EAST & AFRICA: ARRHYTHMIAS MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 378 MIDDLE EAST & AFRICA: ARRHYTHMIAS MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 379 MIDDLE EAST & AFRICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 380 MIDDLE EAST & AFRICA: STRUCTURAL HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 381 MIDDLE EAST & AFRICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2021-2023 (USD MILLION)
  • TABLE 382 MIDDLE EAST & AFRICA: INFLAMMATORY HEART DISEASE MARKET, BY INDICATION, 2024-2029 (USD MILLION)
  • TABLE 383 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2021-2023 (USD MILLION)
  • TABLE 384 MIDDLE EAST & AFRICA: CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024-2029 (USD MILLION)
  • TABLE 385 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 386 CARDIOVASCULAR DEVICES MARKET: DEGREE OF COMPETITION
  • TABLE 387 CARDIOVASCULAR DEVICES MARKET: REGION FOOTPRINT
  • TABLE 388 CARDIOVASCULAR MARKET: PRODUCT FOOTPRINT
  • TABLE 389 CARDIOVASCULAR DEVICES MARKET: INDICATION FOOTPRINT
  • TABLE 390 CARDIOVASCULAR DEVICES MARKET: END-USER FOOTPRINT
  • TABLE 391 CARDIOVASCULAR DEVICES MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 392 CARDIOVASCULAR DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
  • TABLE 393 CARDIOVASCULAR DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 394 CARDIOVASCULAR DEVICES MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 395 CARDIOVASCULAR DEVICES MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 396 CARDIOVASCULAR DEVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 397 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 398 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 399 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 400 MEDTRONIC: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 401 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 402 ABBOTT LABORATORIES: PRODUCTS OFFERED
  • TABLE 403 ABBOTT LABORATORIES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 404 ABBOTT LABORATORIES: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 405 BOSTON SCIENTIFIC CORPORATION.: COMPANY OVERVIEW
  • TABLE 406 BOSTON SCIENTIFIC CORPORATION.: PRODUCTS OFFERED
  • TABLE 407 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 408 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 409 GE HEALTHCARE: COMPANY OVERVIEW
  • TABLE 410 GE HEALTHCARE: PRODUCTS OFFERED
  • TABLE 411 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 412 GE HEALTHCARE: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 413 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 414 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 415 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 416 EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 417 EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED
  • TABLE 418 EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 419 EDWARD LIFESCIENCES CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 420 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 421 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 422 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 423 JOHNSON AND JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • TABLE 424 JOHNSON AND JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 425 JOHNSON AND JOHNSON SERVICES INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 20210-NOVEMBER 2024
  • TABLE 426 JOHNSON AND JOHNSON SERVICES, INC: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 427 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED: COMPANY OVERVIEW
  • TABLE 428 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED: PRODUCTS OFFERED
  • TABLE 429 BAXTER INTENATIONAL, INC.: COMPANY OVERVIEW
  • TABLE 430 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED
  • TABLE 431 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 432 ARTIVION, INC.: COMPANY OVERVIEW
  • TABLE 433 ARTIVION, INC.: PRODUCTS OFFERED
  • TABLE 434 GETINGE AB: COMPANY OVERVIEW
  • TABLE 435 GETINGE AB: PRODUCTS OFFERED
  • TABLE 436 GETINGE AB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 437 GETINGE AB: DEALS, JANUARY 2021-MARCH 2024
  • TABLE 438 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 439 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 440 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 441 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
  • TABLE 442 NIHON KOHDEN CORPORATION: PRODUCTS OFFERED
  • TABLE 443 BIOTRONIK SE & CO.KG.: COMPANY OVERVIEW
  • TABLE 444 BIOTRONIK SE & CO.KG: PRODUCTS OFFERED
  • TABLE 445 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: COMPANY OVERVIEW
  • TABLE 446 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.: PRODUCTS OFFERED
  • TABLE 447 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.:: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 448 MICROPORT SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 449 MICROPORT SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 450 MICROPORT SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 451 ANGIODYNAMICS INC.: COMPANY OVERVIEW
  • TABLE 452 ANGIODYNAMICS INC.: PRODUCTS OFFERED
  • TABLE 453 JAPAN LIFELINE CO., LTD.: COMPANY OVERVIEW
  • TABLE 454 JAPAN LIFELINE CO., LTD.PRODUCTS OFFERED
  • TABLE 455 JAPAN LIFELINE CO., LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 456 W.L. GORE & ASSOCIATES: COMPANY OVERVIEW
  • TABLE 457 W.L. GORE & ASSOCIATES: PRODUCTS OFFERED
  • TABLE 458 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 459 B. BRAUN SE.: PRODUCTS OFFERED

List of Figures

  • FIGURE 1 MARKETS & REGIONS COVERED
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 PRIMARY BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 6 TOP-DOWN APPROACH
  • FIGURE 7 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029)
  • FIGURE 8 CARDIOVASCULAR DEVICES MARKET: CAGR PROJECTIONS
  • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 CARDIAC IMAGING & DIAGNOSTIC DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 CARDIOVASCULAR DEVICES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 CARDIOVASCULAR DEVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 GEOGRAPHIC SNAPSHOT OF CARDIOVASCULAR DEVICES MARKET
  • FIGURE 15 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
  • FIGURE 16 HOSPITALS & CLINICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 17 ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 18 CARDIOVASCULAR DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19 LEADING TRENDS
  • FIGURE 20 CARDIOVASCULAR DEVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 21 NUMBER OF PATENTS PUBLISHED (JANUARY 2014-SEPTEMBER 2024)
  • FIGURE 22 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR CARDIOVASCULAR DEVICES PATENTS (JANUARY 2014-SEPTEMBER 2024)
  • FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR CARDIOVASCULAR DEVICES (JANUARY 2014- JULY 2024)
  • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIOVASCULAR DEVICES
  • FIGURE 25 KEY BUYING CRITERIA FOR TOP 3 END USERS OF CARDIOVASCULAR DEVICES
  • FIGURE 26 CARDIOVASCULAR DEVICES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 CARDIOVASCULAR DEVICES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 28 REVENUE SHIFT FOR CARDIOVASCULAR DEVICES MARKET
  • FIGURE 29 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO (2018-2022)
  • FIGURE 30 CARDIOVASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 31 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET SNAPSHOT
  • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET (2021-2023)
  • FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET (2023)
  • FIGURE 34 RANKING OF KEY PLAYERS IN CARDIOVASCULAR DEVICES MARKET, 2023
  • FIGURE 35 CARDIOVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 36 CARDIOVASCULAR DEVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 37 CARDIOVASCULAR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 CARDIOVASCULAR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 MEDTRONIC: COMPANY SNAPSHOT (2024)
  • FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 43 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 44 GE HEALTHCARE: COMPANY SNAPSHOT (2023)
  • FIGURE 45 TERUMO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 46 EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 47 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 48 JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 BAXTER INTENATIONAL, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 ARTIVION, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 51 GETINGE AB: COMPANY SNAPSHOT (2023)
  • FIGURE 52 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 54 MICROPORT SCIENTIFIC CORPORATION.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 ANGIODYNAMICS INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 JAPAN LIFELINE CO., LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 57 B. BRAUN SE: COMPANY SNAPSHOT (2023)